Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis
Chen Y-L., Gutowska-Owsiak D., Hardman CS., Westmoreland M., MacKenzie T., Cifuentes L., Waithe D., Lloyd-Lavery A., Marquette A., Londei M., Ogg G.
First-in-class clinical trial of IL-33 blockade shows inhibition of neutrophil migration into human skin and modulates atopic dermatitis symptoms.